Medicxi Overview
Medicxi is a European investment firm focused on the life sciences sector, established in 2016 by the former Index Ventures life sciences team. The firm invests in both early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. Medicxi has raised multiple funds, including the €500 million Medicxi V in November 2025, and has created 16 new companies since its previous fundraise. The firm has realized over $1 billion across its portfolio, with notable acquisitions such as ViceBio by Sanofi, Versanis Bio by Eli Lilly, and ProfoundBio by Genmab. Medicxi's investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna (Phathom Pharmaceuticals), and obicetripib (New Amsterdam Pharma).
Is Medicxi the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with Medicxi, along with a list of other relevant VCs, is available on Hopohopo.io.
Medicxi
Investment focus
Invest in
- Baltics
- Nordics
- Western Europe
- Southern Europe
- Central Eastern Europe
Product type
- Drugs / Pharma
Industries / verticals
- BioTech & Life Sciences
Stages
Seed, Series A, Series B or later
First ticket size
€5,000,000 - €22,000,000
How to approach funds like Medicxi
When approaching Medicxi, founders should be prepared to articulate a compelling clinical rationale and a clear path to address significant unmet medical needs. Highlighting robust scientific validation, a differentiated therapeutic approach, and a credible plan for clinical development will resonate. Medicxi values teams with deep domain expertise and a track record of translating science into tangible patient outcomes, so emphasize your team's relevant experience and your strategy for navigating regulatory and commercial milestones.
Find the best-fitting investors for your startup
Stop wasting weeks searching for the right investors. Upload your deck and get matched with investors who actually fit your startup — so you can focus on building, not chasing.
